Technology areas: Chemistry & Materials • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Optima Life Science GmbH is currently managing 2 pending office actions in the Chemistry & Materials technology area. The data shows that 2 distinct examiners are involved in reviewing these cases, suggesting a distribution of the company's intellectual property across different personnel. Furthermore, the workload is spread across 2 distinct art units, which indicates that the technical scope of the applications is diverse within the Chemistry & Materials sector.
OTERO, KENNETH MAX is the busiest examiner for this portfolio, with 1 busiest examiner pending action currently assigned. Since there are 2 pending office actions in total and 2 distinct examiners, each examiner is responsible for 1 case. This distribution means that the company must navigate 2 separate prosecution paths without a single primary examiner overseeing the majority of the work.
For practitioners, the involvement of 2 distinct art units and 2 distinct examiners implies that there is no central point of influence in the current portfolio. The strategy for Optima Life Science GmbH must be adaptable to the various standards of the 2 distinct art units. Success will depend on managing the 2 pending office actions individually, as the 1 busiest examiner pending action under OTERO, KENNETH MAX represents only a portion of the total activity.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTERO, KENNETH MAX | 1 | 52.4% | +43.3% |
| DO, NHAT CHIEU Q | 1 | 64.0% | +48.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690188 | PUNCHING CYLINDER FOR THE ROTARY CUTTING OF A MATERIAL WEB, AND PUNCHING SHEET | DO, NHAT CHIEU Q | 20d |
| 18698278 | METHOD AND DEVICE FOR PRODUCING MEMBRANE ASSEMBLIES | OTERO, KENNETH MAX | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690188 | PUNCHING CYLINDER FOR THE ROTARY CUTTING OF A MATERIAL WEB, AND PUNCHING SHEET | DO, NHAT CHIEU Q | 20d |
| 18698278 | METHOD AND DEVICE FOR PRODUCING MEMBRANE ASSEMBLIES | OTERO, KENNETH MAX | — |
| Art Unit | Apps |
|---|---|
| 1725 | 1 |
| 3724 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698278 | METHOD AND DEVICE FOR PRODUCING MEMBRANE ASSEMBLIES | OTERO, KENNETH MAX | 1725 | §103§112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18690188 | PUNCHING CYLINDER FOR THE ROTARY CUTTING OF A MATERIAL WEB, AND PUNCHING SHEET | DO, NHAT CHIEU Q | 3724 | §102§103§112 | Non-Final OA | 20d | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOptima Life Science GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kenneth Max Otero has the most, with 1 of Optima Life Science GmbH's pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
